Arnaud CHEVROLLIER

Dr. Arnaud CHEVROLLIER

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2011 in Brain
Verified
Journal Article
Open access
PDF file
CRCécile Rouzier
Cécile Rouzier
SBSylvie Bannwarth
Sylvie Bannwarth
ACAnnabelle Chaussenot
Annabelle Chaussenot
ACArnaud CHEVROLLIER
Arnaud CHEVROLLIER
AVAnnie Verschueren
Annie Verschueren
VPVéronique Paquis-Flucklinger
Véronique Paquis-Flucklinger
MFN2 and OPA1 genes encode two dynamin-like GTPase proteins involved in the fusion of the mitochondrial membrane. They have been associated with Charcot–Marie–Tooth disease type 2A and autosomal dominant optic atrophy, respectively. We report a large family with optic atrophy beginning in early childhood, associated with axonal neuropathy and mitochondrial myopathy in adult life. The clinical presentation looks like the autosomal dominant optic atrophy ‘plus’ phenotype linked to OPA1 mutations but is associated with a novel MFN2 missense mutation (c.629A>T, p.D210V). Multiple mitochondrial DNA deletions were found in skeletal muscle and this observation makes MFN2 a novel gene associated with ‘mitochondrial DNA breakage’ syndrome. Contrary to previous studies in patients with Charcot–Marie–Tooth disease type 2A, fibroblasts carrying the MFN2 mutation present with a respiratory chain deficiency, a fragmentation of the mitochondrial network and a significant reduction of MFN2 protein expression. Furthermore, we show for the first time that impaired mitochondrial fusion is responsible for a deficiency to repair stress-induced mitochondrial DNA damage. It is likely that defect in mitochondrial DNA repair is due to variability in repair protein content across the mitochondrial population and is at least partially responsible for mitochondrial DNA instability.

1 June 2011 in Biochimica et Biophysica Acta (BBA) - Bioenergetics
Verified
Journal Article
Closed access
ACArnaud CHEVROLLIER
Arnaud CHEVROLLIER
DLDominique Loiseau
Dominique Loiseau
PRPascal Reynier
Pascal Reynier
GSGeorges Stepien
Georges Stepien

1 December 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
VDValerie Desquiret-Dumas
Valerie Desquiret-Dumas
NGNaïg Gueguen
Naïg Gueguen
GLGéraldine Leman
Géraldine Leman
SBStéphanie Baron
Stéphanie Baron
VNValérie Nivet-Antoine
Valérie Nivet-Antoine
VPVincent Procaccio
Vincent Procaccio
Resveratrol (RSV) has been shown to be involved in the regulation of energetic metabolism, generating increasing interest in therapeutic use. SIRT1 has been described as the main target of RSV. However, recent reports have challenged the hypothesis of its direct activation by RSV, and the signaling pathways remain elusive. Here, the effects of RSV on mitochondrial metabolism are detailed both in vivo and in vitro using murine and cellular models and isolated enzymes. We demonstrate that low RSV doses (1–5 μm) directly stimulate NADH dehydrogenases and, more specifically, mitochondrial complex I activity (EC50 ∼1 μm). In HepG2 cells, this complex I activation increases the mitochondrial NAD+/NADH ratio. This higher NAD+ level initiates a SIRT3-dependent increase in the mitochondrial substrate supply pathways (i.e. the tricarboxylic acid cycle and fatty acid oxidation). This effect is also seen in liver mitochondria of RSV-fed animals (50 mg/kg/day). We conclude that the increase in NADH oxidation by complex I is a crucial event for SIRT3 activation by RSV. Our results open up new perspectives in the understanding of the RSV signaling pathway and highlight the critical importance of RSV doses used for future clinical trials.

1 December 2014 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
ECEstelle Colin
Estelle Colin
ECEvelyne Huynh Cong
Evelyne Huynh Cong
GMGéraldine Mollet
Géraldine Mollet
AGAgnès Guichet
Agnès Guichet
OGOlivier Gribouval
Olivier Gribouval
CACorinne Antignac
Corinne Antignac

21 May 2008 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
ACArnaud CHEVROLLIER
Arnaud CHEVROLLIER
VGVirginie Guillet
Virginie Guillet
DLDominique Loiseau
Dominique Loiseau
NGNaïg Gueguen
Naïg Gueguen
MCMarie‐Anne Pou de Crescenzo
Marie‐Anne Pou de Crescenzo
PRPascal Reynier
Pascal Reynier

23 September 2017 in Brain
Verified
Journal Article
Open access
PDF file
SGSylvie Gerber
Sylvie Gerber
MCMajida Charif
Majida Charif
ACArnaud CHEVROLLIER
Arnaud CHEVROLLIER
TCTanguy Chaumette
Tanguy Chaumette
CAClaire Angebault
Claire Angebault
GLGuy Lenaers
Guy Lenaers
Dominant optic atrophy is a blinding disease due to the degeneration of the retinal ganglion cells, the axons of which form the optic nerves. In most cases, the disease is caused by mutations in OPA1, a gene encoding a mitochondrial large GTPase involved in cristae structure and mitochondrial network fusion. Using exome sequencing, we identified dominant mutations in DNM1L on chromosome 12p11.21 in three large families with isolated optic atrophy, including the two families that defined the OPA5 locus on chromosome 19q12.1-13.1, the existence of which is denied by the present study. Analyses of patient fibroblasts revealed physiological abundance and homo-polymerization of DNM1L, forming aggregates in the cytoplasm and on highly tubulated mitochondrial network, whereas neither structural difference of the peroxisome network, nor alteration of the respiratory machinery was noticed. Fluorescence microscopy of wild-type mouse retina disclosed a strong DNM1L expression in the ganglion cell layer and axons, and comparison between 3-month-old wild-type and Dnm1l+/− mice revealed increased mitochondrial length in retinal ganglion cell soma and axon, but no degeneration. Thus, our results disclose that in addition to OPA1, OPA3, MFN2, AFG3L2 and SPG7, dominant mutations in DNM1L jeopardize the integrity of the optic nerve, suggesting that alterations of the opposing forces governing mitochondrial fusion and fission, similarly affect retinal ganglion cell survival.